MOTS-c

MOTS-c is encoded within the mitochondrial 12S rRNA gene — one of the small handful of peptides the mitochondrion writes itself. Under metabolic stress it moves from mitochondrion to nucleus and binds antioxidant response elements alongside ATF1, driving a stress-adaptive transcriptional programme. Its best-characterised downstream effect is inhibition of the folate–methionine cycle, which raises AICAR and thereby activates AMPK, producing increased glucose uptake, fatty acid oxidation and mitochondrial biogenesis. Circulating MOTS-c rises acutely with exercise in humans and falls with age and with insulin resistance, which is the basis for calling it an exercise-mimetic. In mice, MOTS-c injections restored running capacity and metabolic health in old animals; the human data are still correlational.

Targets: AMPK, Folate–methionine one-carbon cycle, ATF1 / antioxidant response elements, GLUT4-mediated glucose uptake

• · The widespread 5-10 mg/day figure comes from community practice, not from any human trial. It is a scaled guess from rodent work at 15 mg/kg.
• · Mirrors the intermittent 3x/week dosing used in the mouse ageing studies, which is the closest thing to a rationale that exists.

Work out your exact syringe units →

• commonInjection-site stinging— MOTS-c solutions are often noted as slightly more irritating than average.
• uncommonTransient fatigue or heavy legs in the first few days— Reported anecdotally; mechanism unclear.
• uncommonMild hypoglycaemic feelings when fasted— Plausible given AMPK activation and increased glucose uptake.
• uncommonHeadache

• Type 1 diabetes or anyone on insulin without glucose monitoring — increased glucose uptake stacks with insulin unpredictably.
• Pregnancy and breastfeeding — no data.

• redundantmetformin — Both converge on AMPK; running them together adds mechanism overlap rather than new benefit, and may compound the blunting of training adaptations.
• synergy5-amino-1mq — Commonly stacked in metabolic protocols targeting NNMT and mitochondrial output from different angles.
• synergysemaglutide — Sometimes added to incretin protocols for metabolic flexibility, though there is no trial evidence for the combination.

• · Fasting glucose and HbA1c if you are using it for metabolic reasons — those are the endpoints it should plausibly move.
• · Fasting insulin and HOMA-IR if available.
• · Objective training data (VO2, time to exhaustion, session RPE) rather than feel.

Not approved anywhere for human use; sold as a research chemical.

• Lee et al. 2015, Cell Metabolism — MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance (preclinical)
• Reynolds et al. 2021, Nature Communications — MOTS-c as an exercise-induced regulator of metabolic homeostasis and physical capacity (preclinical)
• Merry et al., review of mitochondrial-derived peptides in ageing and metabolism (review)

MOTS-c is one of a handful of peptides the mitochondrion encodes itself, read out of an alternative open reading frame inside the 12S rRNA gene, and the interesting thing about it is that it is a retrograde signal — information travelling from mitochondrion to nucleus rather than the other way. Under metabolic stress it translocates to the nucleus and co-occupies antioxidant response elements with ATF1, driving a stress-adaptive transcriptional programme. The metabolic arm runs differently: MOTS-c inhibits the folate-methionine one-carbon cycle at the level of purine biosynthesis, which causes AICAR to accumulate, and AICAR is the endogenous AMP-mimetic that activates AMPK. So the AMPK activation is not receptor-mediated — it is a metabolite-mediated consequence of blocking a biosynthetic pathway, which is a genuinely unusual mechanism and explains why the effect looks like exercise rather than like a drug. Downstream you get GLUT4 translocation and increased glucose uptake, increased fatty acid oxidation, and mitochondrial biogenesis signalling. A 2024 iScience paper added a direct protein target: MOTS-c binds and activates casein kinase 2 (CK2) in skeletal muscle, and the naturally occurring K14Q variant, which loses that binding, also loses the protective phenotype. That is the strongest evidence to date that MOTS-c has a specific molecular partner rather than acting only through bulk metabolic perturbation. Clinically the picture is coherent but thin: circulating MOTS-c rises with acute exercise, falls with age, and is lower in insulin resistance. In mice, injected MOTS-c restored running capacity in old animals and improved metabolic health. In humans, every result is an association.

The dominant failure mode is spending real money on a compound with no human efficacy data and no way to tell whether it worked. The 5-10 mg per day figure everyone uses is a naive body-weight scale-up from mouse studies dosed at around 15 mg/kg, and naive mg/kg scaling from mouse to human is wrong by roughly an order of magnitude in the direction that means the human doses in circulation are probably far below anything the animal data support — or, if the peptide behaves differently, far above. Nobody knows which. The second failure mode is the hypoglycaemia one: MOTS-c increases glucose uptake, and people running it fasted, on a deficit, and on a GLP-1 or insulin at the same time do occasionally get properly symptomatic. If you are on insulin, monitor. The third is oxidation — two methionines mean this peptide degrades faster in badly stored solution than most, and a vial that has been sitting reconstituted at room temperature for a fortnight is not the compound you think it is. The fourth is diagnostic: because MOTS-c produces a mild subjective energy effect that is indistinguishable from placebo, expectation, or the training block you started at the same time, almost nobody who runs it can tell you whether it did anything. Bloodwork is the only way out of that.

• Casein kinase 2 (CK2) — Direct binding demonstrated; no published Kd that I could locate.

  Binding activates CK2 in skeletal muscle. The K14Q polymorphic variant shows reduced CK2 binding and loses the protective muscle phenotype, which is the cleanest structure-function link the peptide has.

• Folate-methionine one-carbon cycle / de novo purine biosynthesis — Pathway-level inhibition; not a defined receptor interaction.

  Blocking flux causes AICAR to accumulate. AICAR is an endogenous AMP mimetic, and this is the actual route to AMPK activation — MOTS-c does not bind AMPK.

• AMPK (indirect, via AICAR) — No direct binding.

  Increased glucose uptake via GLUT4 translocation, increased fatty acid oxidation, suppression of anabolic signalling, mitochondrial biogenesis signalling. This is the whole exercise-mimetic phenotype.

• ATF1 and antioxidant response elements (nuclear) — Co-occupancy demonstrated by ChIP; no affinity constant published.

  Stress-adaptive transcriptional programme. MOTS-c physically relocates to the nucleus under metabolic stress to do this — it is a retrograde mitochondrial-to-nuclear signal.

• No identified cell-surface receptor — None known.

  This matters practically: there is no receptor occupancy model to reason about, no saturation curve, and therefore no principled basis for any of the doses people use.

Days one to five of a loading block: some people report a transient heaviness or flat feeling in training, which is unexplained and usually passes. Week one to two: this is where the subjective energy and training-tolerance reports cluster. It is also exactly the window where a new injectable, a new training block and a new expectation all coincide, so treat it sceptically. Week four to eight: if fasting insulin or HOMA-IR is going to move, this is when it becomes measurable. Week twelve and beyond: HbA1c integrates. Nothing about the longevity claim is observable on any human timescale, and the animal data that generated it involved intermittent dosing in already-old mice, which is not the population buying it.

The commonest stack is MOTS-c with 5-amino-1MQ, which is coherent in the sense that they hit metabolic rate from different directions (AMPK signalling versus NNMT inhibition) and incoherent in the sense that neither has human interventional data, so you are compounding two unknowns. Pairing with SS-31 is popular and is the most defensible combination in this class on mechanism alone — SS-31 fixes inner-membrane structure and electron transport efficiency, MOTS-c signals for biogenesis and substrate flux, and they do not overlap. No trial has tested it. Metformin is the one to think about properly: both converge on AMPK, so the marginal benefit of adding MOTS-c to metformin is unclear, and there is a real literature showing metformin blunts the adaptive response to aerobic training. If your goal is training adaptation, stacking two AMPK activators is more likely to work against you than for you. With GLP-1 agonists, MOTS-c is sometimes added for metabolic flexibility during a deficit; that is a reasonable-sounding idea with zero evidence and a real hypoglycaemia consideration if you are also on insulin. Timing convention is pre-training on training days, on the logic that you are amplifying an exercise signal, and that logic is at least consistent with the biology even though nobody has tested whether timing matters.

Against SS-31: not close on evidence. SS-31 is an FDA-approved drug with a published label, human pharmacokinetics and phase 3 data; MOTS-c has rodent efficacy and human association studies. They are frequently discussed in the same breath and they are not in the same evidence tier. Against metformin: metformin has decades of human outcome data, costs almost nothing, and hits the same AMPK endpoint. If your goal is insulin sensitivity and nothing else, metformin is the rational choice and MOTS-c is the expensive speculative one. Against actual exercise: MOTS-c is literally characterised as an exercise-induced signal, and exercise produces it endogenously along with everything else exercise does. Nobody has shown that injecting it substitutes for any part of that. Against humanin and the other mitochondrial-derived peptides: MOTS-c has the most complete mechanistic story of the family, the only identified direct protein partner, and the only human polymorphism data linked to a functional phenotype. Within a weak class, it is the strongest member.

$60–$200/month. Not verified against live vendor pricing this session. Based on typical 10 mg vial pricing, a 10-day loading block at 5-10 mg/day consumes 50-100 mg, and maintenance at 5 mg three times weekly consumes roughly 60 mg per month. The range reflects the spread between bulk research-chemical pricing and compounding-pharmacy or clinic pricing, which can be several times higher.

• ?No human pharmacokinetic study of injected MOTS-c has been published. The one-to-two-hour half-life is inferred from the decay of an exercise-induced endogenous rise, not measured after a dose.
• ?No human interventional trial of MOTS-c has reported results. Every efficacy claim is rodent or cell-based.
• ?The 5-10 mg/day community dose has no derivation anyone can point to beyond naive mouse-to-human mg/kg scaling, which is not a valid conversion.
• ?Whether MOTS-c crosses the blood-brain barrier is unknown.
• ?Whether pre-training timing matters at all has never been tested.
• ?Bioavailability by the subcutaneous route is unmeasured.
• ?Whether the peptide's effects require the intracellular nuclear translocation step, and therefore whether an extracellularly delivered peptide reaches the compartment where it acts, is not clearly established for exogenous dosing.
• ?The direction of the CK2 finding is new (2024) and has not yet been independently replicated as far as I could determine.
• ?Cost figures are estimates and were not verified against live vendor pricing.

• The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, Mehta H, Hevener AL, de Cabo R, Cohen P, Cell Metabolism, 2015 · PMID 25738459

  The discovery paper. Establishes the folate-methionine cycle inhibition, AICAR accumulation and AMPK activation mechanism, and the metabolic phenotype in mice. This is the foundation of everything else.

• MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, Cohen P, Graham NA, Benayoun BA, Merry TL, Lee C, Nature Communications, 2021 · PMID 33473109

  The exercise-mimetic paper. Shows exercise induces endogenous MOTS-c in human skeletal muscle and circulation, and that injected MOTS-c improves physical capacity in mice at multiple ages. The human component here is observational — this is where the exercise-induction claim comes from, and it is not an interventional human trial.

• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 Kumagai H, Kim SJ, Miller B, et al., iScience, 2024 · PMID 39559755

  The first identified direct protein-binding partner. Also shows the K14Q variant loses CK2 binding and the protective phenotype, which links the human polymorphism data to a molecular mechanism.

• The MOTS-c K14Q polymorphism in the mtDNA is associated with muscle fiber composition and muscular performance Kumagai H, Natsume T, Kim SJ, et al., Biochimica et Biophysica Acta - General Subjects, 2022 · PMID 34728329

  The East Asian-specific m.1382A>C variant, which changes lysine 14 to glutamine, associates with fast-twitch fibre predominance and sprint/power performance in men. This is the best human genetic evidence that MOTS-c sequence matters physiologically.

• MOTS-c, the most recent mitochondrial derived peptide in human aging and age-related diseases Mohtashami Z, Singh MK, Salimiaghdam N, Ozgul M, Kenney MC, International Journal of Molecular Sciences, 2022 · PMID 36233287

  A good current review that also states the 16-residue sequence explicitly, which is how the sequence in this record was confirmed.

• Mitochondrial-derived microproteins: from discovery to function Yen K, Miller B, Kim SJ, Cohen P, et al., Trends in Genetics, 2025 · PMID 39690001

  The current state-of-the-field review for the whole mitochondrial-derived peptide family from the group that discovered most of them. Useful for calibrating how much of this is established versus emerging.